Literature DB >> 29392700

Orthotopic Patient-Derived Glioblastoma Xenografts in Mice.

Zhongye Xu1, Michael Kader1, Rajeev Sen1, Dimitris G Placantonakis2,3,4,5,6.   

Abstract

Patient-derived xenografts (PDX) provide in vivo glioblastoma (GBM) models that recapitulate actual tumors. Orthotopic tumor xenografts within the mouse brain are obtained by injection of GBM stem-like cells derived from fresh surgical specimens. These xenografts reproduce GBM's histologic complexity and hallmark biological behaviors, such as brain invasion, angiogenesis, and resistance to therapy. This method has become essential for analyzing mechanisms of tumorigenesis and testing the therapeutic effect of candidate agents in the preclinical setting. Here, we describe a protocol for establishing orthotopic tumor xenografts in the mouse brain with human GBM cells.

Entities:  

Keywords:  Glioblastoma; Mouse brain; Orthotopic; Tumor model

Mesh：

Year:  2018        PMID： 29392700     DOI： 10.1007/978-1-4939-7659-1_14

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  12 in total

Review 1.  Multidimensional communication in the microenvirons of glioblastoma.

Authors:  Marike L Broekman; Sybren L N Maas; Erik R Abels; Thorsten R Mempel; Anna M Krichevsky; Xandra O Breakefield
Journal:  Nat Rev Neurol       Date:  2018-08       Impact factor: 42.937

2.  An in silico glioblastoma microenvironment model dissects the immunological mechanisms of resistance to PD-1 checkpoint blockade immunotherapy.

Authors:  Zhuoyu Zhang; Lunan Liu; Chao Ma; Xin Cui; Raymond H W Lam; Weiqiang Chen
Journal:  Small Methods       Date:  2021-04-22

3.  siRNA nanoparticle suppresses drug-resistant gene and prolongs survival in an orthotopic glioblastoma xenograft mouse model.

Authors:  Kui Wang; Forrest M Kievit; Peter A Chiarelli; Zachary R Stephen; Guanyou Lin; John R Silber; Richard G Ellenbogen; Miqin Zhang
Journal:  Adv Funct Mater       Date:  2020-11-06       Impact factor: 18.808

4.  Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.

Authors:  Junfeng Zhang; Wei Xue; Kai Xu; Liang Yi; Yu Guo; Tian Xie; Haipeng Tong; Bo Zhou; Shunan Wang; Qing Li; Heng Liu; Xiao Chen; Jingqin Fang; Weiguo Zhang
Journal:  Theranostics       Date:  2020-06-05       Impact factor: 11.556

5.  PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity.

Authors:  Shiv K Gupta; Emily J Smith; Ann C Mladek; Shulan Tian; Paul A Decker; Sani H Kizilbash; Gaspar J Kitange; Jann N Sarkaria
Journal:  Front Oncol       Date:  2019-01-22       Impact factor: 6.244

6.  Redistribution of EZH2 promotes malignant phenotypes by rewiring developmental programmes.

Authors:  Thomas Mortimer; Elanor N Wainwright; Harshil Patel; Bernard M Siow; Zane Jaunmuktane; Sebastian Brandner; Paola Scaffidi
Journal:  EMBO Rep       Date:  2019-08-29       Impact factor: 8.807

7.  Development of a Microfluidic Culture Paradigm for Ex Vivo Maintenance of Human Glioblastoma Tissue: A New Glioblastoma Model?

Authors:  Farouk Olubajo; Shailendra Achawal; John Greenman
Journal:  Transl Oncol       Date:  2019-11-11       Impact factor: 4.243

Review 8.  Patient-Derived Glioma Models: From Patients to Dish to Animals.

Authors:  Cintia Carla da Hora; Markus W Schweiger; Thomas Wurdinger; Bakhos A Tannous
Journal:  Cells       Date:  2019-09-30       Impact factor: 6.600

9.  Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy.

Authors:  Xin Cui; Chao Ma; Varshini Vasudevaraja; Jonathan Serrano; Jie Tong; Yansong Peng; Michael Delorenzo; Guomiao Shen; Joshua Frenster; Renee-Tyler Tan Morales; Weiyi Qian; Aristotelis Tsirigos; Andrew S Chi; Rajan Jain; Sylvia C Kurz; Erik P Sulman; Dimitris G Placantonakis; Matija Snuderl; Weiqiang Chen
Journal:  Elife       Date:  2020-09-10       Impact factor: 8.140

10.  Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study.

Authors:  Benjamin Stegen; Alexander Nieto; Valerie Albrecht; Jessica Maas; Michael Orth; Klement Neumaier; Sabine Reinhardt; Moritz Weick-Kleemann; Wilfried Goetz; Merle Reinhart; Katia Parodi; Claus Belka; Maximilian Niyazi; Kirsten Lauber
Journal:  Radiat Oncol       Date:  2020-01-22       Impact factor: 3.481
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.